Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Cesca van de Ven

Postdoc, supervision leukemic niche research line
Cesca van de Ven
Cesca van de Ven

Humanized models to study the leukemic microenvironment

Dr. Cesca van de Ven completed a BSc in Biology in 2005, followed by a MSc degree in Developmental Biology and Biomedical Genetics in 2007, both at Utrecht University. From 2007-2011, she conducted her PhD research into the genetic networks controlling axial extension during embryonic development, at the Hubrecht Institute under supervision of dr. Jacqueline Deschamps and Prof. dr. Hans Clevers, obtaining her PhD in 2011 at the faculty of Medicine of Utrecht University.

Subsequently, in 2012 she joined the group of Prof. dr. Monique den Boer as a Postdoc, first at the research laboratory of Pediatric Oncology at the Erasmus MC in Rotterdam, and from 2018 in the Princess Máxima Center for Pediatric oncology.

Specializing in the role of the microenvironment in children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), she investigates how targeting the microenvironment can contribute to a higher cure rate for children with this disease and how to achieve this cure with fewer and less severe side effects of chemotherapy.

  • Tracked ultrasound registration for intraoperative navigation during pediatric bone tumor resections with soft tissue components: a porcine cadaver study

    • nov. 2023
    • J M, van der Zee, et al
    • International journal of computer assisted radiology and surgery
  • Various cell types in the bone marrow sustain primary B-cell precursor acute lymphoblastic leukemia

    • jan. 2023
    • Mandy, Smeets, et al
    • bioRxiv
  • Ibrutinib is not an effective drug in primografts of TCF3-PBX1

    • okt. 2020
    • Cesca, van de Ven, et al
    • Translational oncology
  • RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

    • apr. 2018
    • I S, Jerchel, et al
    • Leukemia
  • JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia

    • okt. 2017
    • Elisabeth M P, Steeghs, et al
    • Oncotarget
View all publications